Integrin αvβ3 is a Potential Therapeutic Target in Cholangiocarcinoma

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Integrin αvβ3 is a cell surface receptor overexpressed in cancers, promoting tumor growth and metastasis.
• Thyroid hormone and epidermal growth factor (EGF) interact with integrin αvβ3, influencing cancer cell signaling and proliferation.
• Thyroxine (T4) analogue, tetraiodothyronine (tetrac), inhibits integrin αvβ3 binding, suggesting therapeutic potential.

Purpose of the Study:

• Investigate the pathogenic role of integrin αvβ3 in cholangiocarcinoma.
• Explore the therapeutic potential of targeting integrin αvβ3 with tetrac derivatives.

Main Methods:

• Analysis of clinical cholangiocarcinoma samples to study integrin αvβ3 interactions.
• Investigated the effects of thyroxine and EGF on PD-L1 expression and signaling pathways.
• Evaluated the anti-proliferative effects of lipo-tetrac and its Dox-derivative in vitro and in xenograft models.

Main Results:

• Integrin αvβ3 crosstalks with EGFR and thyroid hormone/EGF signaling pathways in cholangiocarcinoma progression.
• Thyroxine and EGF stimulate PD-L1 expression, promoting cancer growth; thyroxine-induced PD-L1 localizes in the nucleus, while EGF-induced PD-L1 affects cytosolic and nuclear pathways.
• Targeting integrin αvβ3 with lipo-tetrac and its Dox-derivative demonstrated significant anti-proliferative effects.

Conclusions:

• Integrin αvβ3 plays a critical role in cholangiocarcinoma pathogenesis through its interaction with growth factors and signaling networks.
• Tetrac and its derivatives represent a promising therapeutic strategy for cholangiocarcinoma by inhibiting integrin αvβ3.
• This study provides a foundation for developing novel targeted therapies for cholangiocarcinoma.